Press Release

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, November 14th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for second quarter of financial year 2026.

NATCO records ₹1,463 Crore consolidated revenue and ₹517.9 Crore of profit after tax for Q2FY26

NATCO recorded consolidated total revenue of INR 1,463.0 Crore for the quarter ended on 30th September 2025 as against INR 1,434.9 crore as of 30th September 2024. EBITDA (including other income) for the quarter was at INR 679.2 Crore with margins at 46.4%. The net profit for the period, on a consolidated basis was INR 517.9 Crore.

During the quarter, the Company has incurred substantial R&D expenses on bioequivalence and one-time employee bonus, in addition to other business-related provisions.

The Board of Directors have declared an interim dividend of INR 1.5 per equity share of INR 2 each during Q2FY26.

Segmental Revenue Split (INR Crore)

Segment	Q2FY26	Q1FY26	Q2FY25
Active Pharmaceutical Ingredients (API)	53.9	52.6	49.6
Domestic Formulations	105.4	107.0	102.3
Formulations export (Incl. profit share and subs)	1,147.0	1,126.5	1,211.3
Crop Health Sciences (CHS)	52.4	34.7	14.1
Other operating and non-operating income	104.3	69.8	57.6
Total	**1,463.0**	**1,390.6**	**1,434.9**

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter).